Research location
Taunton
United Kingdom
Advertisement
Research activity in Taunton
United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 67 trials and 67 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Taunton
67 linked trials · page 1 of 2A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · 2025-03-27 · 1 site observation
RECRUITING
Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary DiseaseNCT06347536 · 2025-01-30 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation
RECRUITING
Intensive Weight Loss Intervention Versus Bariatric Surgery for Adults With Severe and Complex Obesity: the LightBAR Randomised TrialNCT06309238 · 2024-05-08 · 1 site observation
RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864 · 2023-11-23 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30 · 1 site observation
RECRUITING
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant ChemotherapyNCT04109079 · 2021-02-26 · 1 site observation
RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNCT04104776 · 2019-09-18 · 1 site observation
RECRUITING
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · 2025-02-10 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28 · 1 site observation
COMPLETED
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNCT05901649 · 2023-07-05 · 1 site observation
COMPLETED
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · 2023-02-01 · 1 site observation
COMPLETED
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · 2022-11-01 · 1 site observation
ACTIVE_NOT_RECRUITING
REported Outcomes in COPD With Trixeo in Real worlDNCT05213611 · 2022-08-11 · 1 site observation
COMPLETED
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomNCT04667312 · 2021-06-24 · 1 site observation
COMPLETED
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · 2021-05-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesityNCT04788511 · 2021-03-16 · 1 site observation
COMPLETED
PreOperative Endocrine Therapy for Individualised Care With AbemaciclibNCT04584853 · 2020-12-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.NCT04564742 · 2020-12-22 · 1 site observation
COMPLETED
Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative ResearchNCT04590976 · 2020-12-03 · 1 site observation
COMPLETED
AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19NCT04516759 · 2020-08-12 · 1 site observation
COMPLETED
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibNCT04421963 · 2020-08-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Microbiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08 · 1 site observation
UNKNOWN
CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)NCT04226248 · 2020-01-02 · 1 site observation
COMPLETED
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerNCT04025879 · 2019-11-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548935 · 2018-06-04 · 1 site observation
COMPLETED
Paediatric Use of the Abbott Sensor Based Glucose Monitoring SystemNCT03433573 · 2018-02-16 · 1 site observation
COMPLETED
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)NCT03358472 · 2017-12-01 · 1 site observation
COMPLETED
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455 · 2017-11-07 · 1 site observation
COMPLETED
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934 · 2017-06-13 · 1 site observation
COMPLETED
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02952534 · 2017-02-15 · 1 site observation
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeNCT03000192 · 2016-08-01 · 1 site observation
UNKNOWN
Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's DiseaseNCT02787590 · 2016-03-08 · 1 site observation
COMPLETED
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 DiabetesNCT02607865 · 2016-02-15 · 1 site observation
COMPLETED
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal InsulinNCT02967211 · 2015-12-21 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.